The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: Report from the clinical and laboratory standards institute methods development and standardization working group

Romney M. Humphries, Susan Kircher, Andrea Ferrell, Kevin M. Krause, Rianna Malherbe, Andre Hsiung, Carey Ann D. Burnham

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Expedited pathways to antimicrobial agent approval by the U.S. Food and Drug Administration (FDA) have led to increased delays between drug approval and the availability of FDA-cleared antimicrobial susceptibility testing (AST) devices. Antimicrobial disks for use with disk diffusion testing are among the first AST devices available to clinical laboratories. However, many laboratories are reluctant to implement disk diffusion testing for a variety of reasons, including dwindling proficiency with this method, interruptions of the laboratory workflow, uncertainty surrounding the quality and reliability of disk diffusion tests, and a perceived need to report MIC values to clinicians. This minireview provides a report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group on the current standards and clinical utility of disk diffusion testing.

Original languageEnglish
Article numbere00437-18
JournalJournal of clinical microbiology
Volume56
Issue number8
DOIs
StatePublished - Aug 2018

Keywords

  • Antimicrobial susceptibility testing
  • CLSI
  • Disk diffusion
  • EUCAST
  • FDA

Fingerprint Dive into the research topics of 'The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: Report from the clinical and laboratory standards institute methods development and standardization working group'. Together they form a unique fingerprint.

Cite this